---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-253747"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:54:53.396002+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AlloVir to merge with Kalaris in all-stock deal; Kalaris stockholders to own ~75% of combined company

## Summary
- AlloVir acquires Kalaris; pre-merger AlloVir stockholders own ~25.05%, Kalaris ~74.95% on fully diluted basis, subject to net cash adjustments.
- Combined company expected to have ~$100M cash at close (expected Q1 2025), providing runway into Q4 2026.
- Pipeline focuses on TH103 (anti-VEGF fusion protein) for neovascular AMD; Phase 1 data expected Q3 2025; also planned for DME and RVO.
- Stockholders owning 87.4% of Kalaris and 29.4% of AlloVir have entered support agreements to vote in favor.
- Post-close company to rename Kalaris Therapeutics, trade on Nasdaq under ticker KLRS.

## SEC filing metadata
- accession: 0001193125-24-253747
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/0001193125-24-253747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/d870301d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-253747
- JSON: https://secwatch.observer/filing/0001193125-24-253747.json
- Plain text: https://secwatch.observer/filing/0001193125-24-253747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.